ConductScience.org, home

Trial · NCT03329508

Results by group20

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160).P2B001-7.98Standard Error 0.60score on a scale
Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160).Rasagiline Capsule-4.69Standard Error 0.61score on a scale
Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160).Pramipexole Capsule-5.32Standard Error 0.61score on a scale
Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score (Defined as Sum of Parts II and III, Scores (0-160).Pramipexole Extended Release-8.35Standard Error 0.86score on a scale
Change in Epworth Sleepiness Scale (ESS) Score.P2B001-0.33Standard Error 0.25score on a scale
Change in Epworth Sleepiness Scale (ESS) Score.Rasagiline Capsule-0.81Standard Error 0.26score on a scale
Change in Epworth Sleepiness Scale (ESS) Score.Pramipexole Capsule0.39Standard Error 0.25score on a scale
Change in Epworth Sleepiness Scale (ESS) Score.Pramipexole Extended Release2.33Standard Error 0.36score on a scale
Change From Baseline to Week 12 in Total UPDRS III MotorP2B001-5.82Standard Error 0.47score on a scale
Change From Baseline to Week 12 in Total UPDRS III MotorRasagiline Capsule-4.07Standard Error 0.48score on a scale
Change From Baseline to Week 12 in Total UPDRS III MotorPramipexole Capsule-4.30Standard Error 0.48score on a scale
Change From Baseline to Week 12 in Total UPDRS III MotorPramipexole Extended Release-6.36Standard Error 0.68score on a scale
Change From Baseline to Week 12 in Total UPDRS II ADLP2B001-2.14Standard Error 0.22score on a scale
Change From Baseline to Week 12 in Total UPDRS II ADLRasagiline Capsule-0.62Standard Error 0.22score on a scale
Change From Baseline to Week 12 in Total UPDRS II ADLPramipexole Capsule-0.97Standard Error 0.22score on a scale
Change From Baseline to Week 12 in Total UPDRS II ADLPramipexole Extended Release-2.02Standard Error 0.31score on a scale
Change From Baseline to End of Week 12 Visit in ADL Subscale of PDQ39P2B001-5.30Standard Error 0.89score on a scale
Change From Baseline to End of Week 12 Visit in ADL Subscale of PDQ39Rasagiline Capsule-2.04Standard Error 0.92score on a scale
Change From Baseline to End of Week 12 Visit in ADL Subscale of PDQ39Pramipexole Capsule-3.40Standard Error 0.90score on a scale
Change From Baseline to End of Week 12 Visit in ADL Subscale of PDQ39Pramipexole Extended Release-3.12Standard Error 1.27score on a scale

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03329508/results